Lawler PR, Goligher EC, Berger JS, et al. - Among patients with coronavirus disease 2019 (COVID-19), there may be a contribution of thrombosis and inflammation to the risk of death and complications and thus therapeutic-dose anticoagulation may aid in improving outcomes in noncritically ill patients.

• This is an open-label, adaptive, multiplatform, controlled trial.

• Patients were administered pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis.

• The initial strategy of therapeutic-dose anticoagulation with heparin results in an elevation in the probability of survival to hospital discharge with decreased use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis.